Conditions: Hepatitis C HCV Chronic Hepatitis C Infection Hepatitis C Genotype 1
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 11
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of ABT-450 with ritonavir (ABT-450/r) dosed in combination with ABT-072 and ribavirin (RBV) in treatment-naïve participants with genotype 1 chronic hepatitis C virus (HCV) infection.

Detailed description:
This was a Phase 2a multicenter, open-label, single arm, combination treatment study of a regimen of ABT-450/r/ABT-072, and ribavirin (RBV) in hepatitis C virus (HCV) genotype 1-(1a or 1b) infected treatment-naïve participants.

Arms:
arm 1: ABT-450/r (150/100 mg) once daily (QD) and ABT-072 (400 mg) QD plus weight-based RBV divided twice daily (BID) for 12 weeks.

Interventions: intervention 1: ABT-450 intervention 2: ABT-072 intervention 3: Ribavirin intervention 4: Ritonavir
Intervention descriptions: intervention 1: tablets intervention 2: tablets intervention 3: tablets intervention 4: capsules

Protocol document: